Position in ALNY
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$4,214
-$9,682 QoQ
Shares Held
14
-66.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#127
of 149 holders
Holding Since
Mar 2023
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Grove Bank & Trust holds $2,547,961 across 9 Biotechnology names. ALNY ranks #7 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,525 | $1,254,243 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,004 | $1,249,573 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
172 | $14,019 | |
| 4 | ABVX |
Abivax S.A.
|
74 | $9,861 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
61 | $5,946 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
200 | $5,060 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
14 | $4,214 | |
| 8 | CVKD |
Cadrenal Therapeutics, Inc.
|
1,000 | $3,340 |
All Filings in ALNY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,214 | 14 | Shares | Sole | 2026-07-07 | |
| 2026-03-31 | $13,896 | 42 | Shares | Sole | 2026-04-08 | |
| 2025-12-31 | $3,578 | 9 | Shares | Sole | 2026-01-08 | |
| 2023-03-31 | $1,201 | 6 | Shares | Sole | 2023-05-10 | |
| No filing history on record for this holder in this stock. | ||||||